On the basis of actual late-stage clinical data, for the first time five distinct drug classes (ketamine, psilocybin, LSD, MDMA, and 5-MeO-DMT) can now be plotted on a credible FDA approval timeline.
Estimated market entry
J&J's Spravato: already approved
Compass' COMP360: Q1-Q2 2027
Usona's psilocybin : mid-20271
Definium's DT120: Q4 20272
AtaiBeckley's BPL-003: 20293
Resilient's MDMA: 20304
Tier 1: Already approved
Because it established the regulatory template, esketamine (Spravato, J&J, multiple doses, TRD and MDD with acute suicidal ideation) is the benchmark every other compound in this piece is measured against. The original 2019 NDA approval was granted for TRD, with esketamine required to be taken alongside an oral antidepressant rather than as a standalone treatment, using a multi-dose induction and maintenance protocol: twice weekly for four weeks, once weekly through week eight, then biweekly or weekly thereafter. The January 2025 supplemental approval expanded the label to monotherapy for the same population, retaining the same multi-dose schedule. This is the framework FDA has already accepted for a consciousness-altering drug with dissociation and abuse potential: mandatory in-clinic administration, two hours of post-dose monitoring, certified prescribers and pharmacies, all codified through a REMS program. Every developer now seeking approval for a psychedelic is negotiating a variation of that bargain: how much monitoring is necessary, how long sessions must last, what discharge criteria are required, and what the REMS certification burden on clinicians and facilities should look like. Esketamine answered those questions for one compound. The field is now working out whether those answers generalize.
Tier 2: NDA imminent
Compass Pathways (COMP360, synthetic psilocybin, two doses, TRD) is the most advanced classical psychedelic in the pipeline and the most likely candidate to reach approval first. Two positive Phase 3 studies (COMP005 and COMP006) have now reported, both hitting primary endpoints. Compass has been granted a Commissioner's National Priority Voucher and rolling NDA review, with submission targeted for Q4 2026. The CNPV compresses FDA review to approximately one to two months after submission, making a decision in late Q1 or Q2 2027 a realistic expectation. The safety profile has been unremarkable, the indication is well-defined, and the regulatory relationship appears intact. COMP360's path to the NDA is the most straightforward of any classical psychedelic in this field. Estimated market entry: Q1-Q2 2027.
Usona Institute (psilocybin, single dose, MDD) is the program with the most to offer commercially, if the data cooperate. As a nonprofit operating under Breakthrough Therapy Designation and a Commissioner's National Priority Voucher, Usona is pursuing the MDD indication, a patient population roughly three times larger than TRD. Its Phase 3 uAspire trial completed enrollment with 238 participants, with an updated completion date of January 2027. Topline data have not yet been announced. If results are positive, the CNPV review timeline applies and NDA submission could follow quickly. A positive readout would put Usona in contention for a market entry close behind Compass, targeting an indication with substantially greater commercial and public health scope. Estimated market entry: mid-2027, contingent on positive Phase 3 results.
Tier 3: Phase 3 positive, NDA pathway being shaped
Definium Therapeutics (DT120, LSD, single dose, MDD) entered this tier this week with the positive Emerge Phase 3 readout. The company's immediate next step is a Type B meeting with FDA to align on NDA submission requirements, a process that typically takes several months. The key regulatory question for Definium is whether a single Phase 3 study is sufficient for submission. FDA acting Commissioner Makary has signaled this may soon be official guidance, and CMO Dan Karlin has indicated the company believes Emerge alone, together with open-label extension data from the same study, constitutes an adequate package. If that holds, the NDA timeline compresses significantly. If a second pivotal is required, a confirmatory Phase 3 (Ascend) is already underway, with topline data expected in 2027. Estimated market entry: Q4 2027, with meaningful upside if single-study guidance holds.
“Every developer now seeking approval for a psychedelic is negotiating a variation of the esketamine bargain.”
Tier 4: CRL issued, path unclear
Resilient Pharmaceuticals (midomafetamine, the international nonproprietary name for MDMA, two full-dose sessions with structured psychotherapy, PTSD) is the cautionary case in this field, and its situation has not substantially improved since the August 2024 Complete Response Letter. The FDA's CRL cited unreported adverse events, inadequate durability data beyond 18 weeks, functional unblinding concerns, and selection bias from prior MDMA use in the trial population. The company subsequently cut its workforce by approximately 75% and has been in ongoing FDA engagement since, without announcing a confirmed start date for the additional Phase 3 FDA has requested. The MDMA-assisted therapy PTSD program carries complications the other compounds in this piece do not: the indication is among the most difficult to blind, the entanglement of drug and therapy that drove design concerns is intrinsic to how the program was built, and the reputational damage from the Psychopharmacologic Drugs Advisory Committee review and CRL process has complicated the company's ability to raise and operate at scale. A new Phase 3, if initiated, would likely take three to four years to complete and review. Estimated market entry: 2030 at the earliest, under optimistic assumptions.
Tier 5: Phase 3 underway, watching from a distance
AtaiBeckley (BPL-003, intranasal 5-MeO-DMT, single dose, TRD) holds Breakthrough Therapy Designation and carries one of the most compelling profiles in the field. The Phase 2b study across 193 participants demonstrated rapid antidepressant effects by Day 2 after a single dose, with durability through eight weeks, and Phase 3 initiation was targeted for Q2 2026 following a successful FDA End-of-Phase 2 meeting. The company has guided cash runway into early 2029, consistent with Phase 3 topline readouts before that date. Given a typical Phase 3 execution timeline of two to three years from initiation, plus NDA preparation and review, a realistic approval window opens in 2029, assuming clean data. Estimated market entry: 2029.
What the timeline reveals
The ordering above reflects a complex interaction between clinical results, regulatory relationship, indication difficulty, mechanism, and institutional factors that are often underweighted in pipeline analyses.
Esketamine is approved but commercially constrained by its multi-dose requirement, REMS friction, and the structural limitation of needing repeated in-clinic visits. The classical psychedelics are making a direct case that one or two doses may achieve comparable or superior durability. Whether payors accept that argument, and what monitoring frameworks they ultimately require, will be as important to commercial outcomes as the approval itself. The Definium Emerge data, with its 5.8-hour mean session clearance, is explicitly designed to begin winning that argument.
MDMA's position in this landscape is the most structurally difficult, and not primarily because of the CRL. The compound's entanglement with psychotherapy, its unblinding problem, and the regulatory precedent that has now accumulated around it make the path to approval categorically harder than it is for the serotonergic compounds. That does not mean it cannot be approved, but the timeline assumptions that circulated in 2022 and 2023 are no longer credible.
BPL-003 trails the field for one reason: AtaiBeckley entered Phase 3 later than its competitors. The compound's profile (single dose, rapid onset, short session duration, durable effects) is arguably among the most commercially attractive in the field. AtaiBeckley is starting Phase 3 in 2026 with better regulatory context than any previous entrant had at the same stage.
[1] and [3]: contingent on positive Phase 3 results.
[2]: with meaningful upside if single-study guidance holds.
[4]: at the earliest, under optimistic assumptions.